TRHR
Thyrotropin-releasing hormone receptor
As of the edition of 20 October 2026, TRHR (thyrotropin-releasing hormone receptor, UniProt P34981) has 3 drugs tested at it and 4 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P34981
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 4
- Disease areas
- Inherited and neonatal; Nervous system; Hormones; Cancer; Lungs and airways
- Registered trials of its drugs
- 16
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Went quiet | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Rovatirelin | Active | Phase 3 | none listed |
| Protirelin | Marketed | Phase 3 | none listed |
| Taltirelin | Went quiet | Phase 4 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Engaged | 1 |
| Undetermined | 2 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| HLB Pharmaceutical | Route A |
The other 3 companies at TRHR
In the product4 companies in all; 3 are not named here, and no score is.
See the 4 companies at TRHR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.